KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone.

Sandra P Smieszek, Sean R Chadwick, Emily L Czeisler, Rosarelis Torres, Haimeng Bai, Changfu Xiao, Christos M Polymeropoulos, Gunther Birznieks, Mihael H Polymeropoulos

Pharmacogenomics J 26(2) 10

PMID41826282
PMCIDPMC12987721
DOI10.1038/s41397-026-00402-8
发表日期2026-03-14
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。
摘要

摘要

Circulating levels of uric acid are influenced by a complex mix of intrinsic and environmental factors, including genetics, diet, and drugs. We analyzed levels of uric acid in a recent phase 3 clinical trial of patients with bipolar mania treated with 24 mg/day of the antipsychotic iloperidone or placebo. Initial results revealed that iloperidone treatment was associated with increases in uric acid from baseline (LS mean change (SE) of 27.2 (-4.93) μmol/L, compared with a change of 0.1 (-4.77) μmol/L for placebo group (LS mean difference (95% CI) = 27.1 (14.94, 39.20), p = <0.0001). Similar results were further observed in a previous phase 3 study of iloperidone treatment of schizophrenia. Pharmacogenetic analysis examining the urate transporter SLC2A9 revealed that iloperidone associated increases were linked to a genetic variant (rs7442295), correlating with both urate levels at baseline and in interaction with iloperidone vs placebo, and a pronounced increase of 35.9 μmol/L (0.67 mg/dL) was seen in iloperidone-treated patients homozygous for the for the rs7442295 (G) allele at the SLC2A9 gene, compared to a decrease of -16.5 (0.31 μmol/L in the corresponding GG placebo group (LS mean difference (95% CI) = 40.79 (14.61, 66.96, p = 0.0024). Further investigation suggested potentially clinically relevant sex differences associated with this variant. Specifically, male GG genotype patients exhibiting more frequent shifts from above the upper limit of normal for iloperidone-treated patients in comparison to female, AG/AA, and placebo groups. Overall, the mechanism of this iloperidone-induced increase in serum urate levels is likely due to decrease in clearance of urate through interaction with the SLC2A9 urate transporter protein. These results may hold clinical significance for patients treated with iloperidone.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Iloperidone treatment resulted in higher change from baseline in urate blood levels as compared to placebo or active comparator ziprasidone after four weeks. a Schematic diagram depicting the 4-week, randomized, blinded, clinical trial design/schema generalizable to both studies. b Mean change from baseline for serum urate for observed cases in Study 3201 and Study 3101. Error bars represent standard error of the mean (SEM). c Least squares (LS) mean difference for change in serum urate and p-values for ANCOVA between iloperidone and placebo. Refer to Tables 1 and 2 for a tabular presentation of numeric results of LS mean P-values, and 95% CIs.
非 KM Figure
Fig. 2Genotype status of urate transporter SLC2A9 variant RS7442295 was associated with baseline uric acid levels. Genotype status of urate transporter SLC2A9 variant RS7442295 ( a ) Baseline uric acid by RS7442295 genotype in Study 3102. b Baseline uric acid by RS7442295 sex and genotype in Study 3102. Scatter plot dots show baseline uric acid concentrations of individuals, and median is depicted by red line. Results were generally similar in Study 3101 (refer to Supplementary Figure 1 ). c Major allele frequencies for SLC2A9 variant rs7442295 according to genetically determined racial groups. Calculated from data retrieved from GnomeAD.
非 KM Figure
Fig. 3Iloperidone and SLC2A9 variant RS7442295 genotype predicts change from baseline in serum urate levels at 4 weeks. A Violin plot showing individual and mean (SEM) change from baseline according to carrier status for variant rs7442295 and treatment group in Study 3201. B Mean (SEM) serum urate levels at baseline and EOS (day 28) according to carrier status for variant rs7442295 and treatment group in Study 3201. C Scatter plot showing individual and median serum urate levels at baseline (black symbols) and EOS (day 28) (white symbols) for patients with GG genotype for variant rs7442295, according to sex, and treatment group in Study 3201. Median depicted by red lines.
非 KM Figure